Some people carry a genetic predisposition to develop osteoarthritis, often leading to severe arthritis even in their 40s or 50s.
But if we can identify those individuals early, and treat them with alpha-2-macroglobulin (A2M), we believe we can protect their joints before it’s too late. It’s not just about extending life – it’s about extending healthspan.
Cruises, hikes, walks with family, everyday activities that make life worth living. That’s the quality of life we’re fighting for. That’s why we’re developing CYT-108, our next-generation A2M therapy designed to address osteoarthritis at its molecular source – not just mask the pain.
